Literature DB >> 18084330

Cyclin D3 action in androgen receptor regulation and prostate cancer.

N A Olshavsky1, E M Groh, C E S Comstock, L M Morey, Y Wang, M P Revelo, C Burd, J Meller, K E Knudsen.   

Abstract

Prostate cancer (PCa) cell proliferation is dependent on activation of the androgen receptor (AR), a ligand-dependent transcription factor. AR activation controls G1-S phase progression through fostering enhanced translation of the D-type cyclins, which promote cell cycle progression through activation of CDK4/6. However, the D-type cyclins harbor additional, CDK4/6 kinase-independent, functions through manipulation of transcription factors, including AR. It was previously established that cyclins D1 and D3 have the potential to modulate AR, and with regard to cyclin D1, disruption of this function occurs in human tumors. Therefore, it was essential to interrogate cyclin D3 function in this tumor type. Here, we show that cyclin D3 is found in association with AR in PCa cells, as mediated through a conserved motif. Cyclin D3 functions to attenuate AR activity through defined mechanisms that include modulation of ligand-dependent conformational changes and modulation of chromatin binding activity. Accumulated cyclin D3 slows cell proliferation in AR-dependent cells, thus suggesting that androgen-induced D-type cyclin production serves to temper the mitogenic response to androgen. Supporting this hypothesis, it is shown that cyclin D3 expression is reduced in primary PCas as a function of tumor grade, and inversely correlates with the proliferative index. In total, these data identify cyclin D3 as a critical modulator of the androgen response, whose deregulation may foster unchecked AR activity in PCa.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18084330     DOI: 10.1038/sj.onc.1210981

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Caspase-2-Based Regulation of the Androgen Receptor and Cell Cycle in the Prostate Cancer Cell Line LNCaP.

Authors:  Agshin F Taghiyev; Oskar W Rokhlin; Rebecca B Glover
Journal:  Genes Cancer       Date:  2011-07

2.  Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function.

Authors:  Clay E S Comstock; Michael A Augello; Matthew J Schiewer; Jason Karch; Craig J Burd; Adam Ertel; Erik S Knudsen; Walter J Jessen; Bruce J Aronow; Karen E Knudsen
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

3.  Requirement for cyclin D3 in germinal center formation and function.

Authors:  Jonathan U Peled; J Jessica Yu; Jeganathan Venkatesh; Enguang Bi; B Belinda Ding; Melissa Krupski-Downs; Rita Shaknovich; Piotr Sicinski; Betty Diamond; Matthew D Scharff; B Hilda Ye
Journal:  Cell Res       Date:  2010-04-20       Impact factor: 25.617

Review 4.  The AR dependent cell cycle: mechanisms and cancer relevance.

Authors:  Matthew J Schiewer; Michael A Augello; Karen E Knudsen
Journal:  Mol Cell Endocrinol       Date:  2011-07-12       Impact factor: 4.102

5.  Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.

Authors:  James L Chen; Jianrong Li; Walter M Stadler; Yves A Lussier
Journal:  J Am Med Inform Assoc       Date:  2011 Jul-Aug       Impact factor: 4.497

6.  Viral cyclins mediate separate phases of infection by integrating functions of distinct mammalian cyclins.

Authors:  Katherine S Lee; Andrea L Suarez; David J Claypool; Taylor K Armstrong; Erin M Buckingham; Linda F van Dyk
Journal:  PLoS Pathog       Date:  2012-02-02       Impact factor: 6.823

7.  Lack of cyclin D3 induces skeletal muscle fiber-type shifting, increased endurance performance and hypermetabolism.

Authors:  Silvia Giannattasio; Giacomo Giacovazzo; Agnese Bonato; Carla Caruso; Siro Luvisetto; Roberto Coccurello; Maurizia Caruso
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

Review 8.  Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis.

Authors:  Bo Wang; Zijian Wang; Lizhi Han; Song Gong; Yanxue Wang; Zhiwen He; Yong Feng; Zhaohui Yang
Journal:  Cancer Cell Int       Date:  2019-06-10       Impact factor: 5.722

9.  Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.

Authors:  M J Schiewer; L M Morey; C J Burd; Y Liu; D E Merry; S-M Ho; K E Knudsen
Journal:  Oncogene       Date:  2008-12-15       Impact factor: 9.867

10.  Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder.

Authors:  Maria V Luna-Velez; Jelmer J Dijkstra; Marina A Heuschkel; Frank P Smit; Guillaume van de Zande; Dominique Smeets; J P Michiel Sedelaar; Michiel Vermeulen; Gerald W Verhaegh; Jack A Schalken
Journal:  Mol Oncol       Date:  2021-05-22       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.